Holland P V
Sacramento Medical Foundation Blood Center, CA 95816-7089.
Arch Pathol Lab Med. 1989 Mar;113(3):285-91.
Transfusion-associated graft-vs-host disease (GVHD) occurs in certain immunocompromised recipients receiving viable lymphocytes in blood and components. Transfusion-associated GVHD affects the skin, liver, gastrointestinal tract, and most importantly, the bone marrow, and results in death in more than 90% of affected patients. The best means to prevent transfusion-associated GVHD is prophylactic irradiation of blood and components to inactivate contained lymphocytes. A dose of 15 Gy delivered by a self-contained cesium 137 irradiator is sufficient to prevent transfusion-associated GVHD. Engraftment of transfused lymphocytes may occur because of HLA similarity between donor and recipient. The HLA differences, however, then facilitate rejection of the host by the engrafted lymphocytes and thus make easier the development of transfusion-associated GVHD or the Japanese equivalent, postoperative erythroderma.
输血相关移植物抗宿主病（GVHD）发生于某些接受含有存活淋巴细胞的血液及成分的免疫功能低下受者。输血相关GVHD会影响皮肤、肝脏、胃肠道，最重要的是影响骨髓，超过90%的受累患者会因此死亡。预防输血相关GVHD的最佳方法是对血液及成分进行预防性照射，以使其中所含淋巴细胞失活。使用自含式铯137辐照器给予15戈瑞的剂量足以预防输血相关GVHD。由于供者与受者之间的人类白细胞抗原（HLA）相似性，输入的淋巴细胞可能会发生植入。然而，HLA差异随后会促使植入的淋巴细胞排斥宿主，从而更容易发生输血相关GVHD或其日本等效病症——术后红皮病。
